Premium
FTS3‐01‐04: FINAL EFFICACY, SAFETY AND BIOMARKER RESULTS OF THE PHASE 2B/3 RANDOMIZED, DOUBLE‐BLINDED, PLACEBO‐CONTROLLED EARLY TRIAL OF ATABECESTAT IN PRECLINICAL ALZHEIMER'S DISEASE
Author(s) -
Henley David,
Sperling Reisa A.,
Aisen Paul S.,
Raman Rema,
Donohue Michael C.,
Ernstrom Karin,
Shi Yingqi,
Karcher Keith,
Raghavan Nandini,
Tymofyeyev Yevgen,
Brashear Robert,
Novak Gerald P.,
Thipphawong John,
Saad Ziad,
Kolb Hartmuth C.,
Romano Gary
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.4621
Subject(s) - placebo , repeatable battery for the assessment of neuropsychological status , medicine , randomized controlled trial , asymptomatic , dementia , biomarker , adverse effect , cognition , repeated measures design , clinical endpoint , neuropsychology , psychiatry , disease , pathology , biochemistry , chemistry , statistics , alternative medicine , mathematics